Merck just delivered news that could reshape how doctors treat one of the deadliest skin cancers.
The 135-year-old drugmaker, founded in 1891 and now based in Rahway, New Jersey, announced a milestone that oncologists have chased for years: a personalized cancer treatment that worked in a large, controlled study.
Investors took notice, sending the blue-chip healthcare stock higher by 12.6% on Aug. 19.
Here is what happened, why it matters, and what it could mean for the healthcare giant’s next chapter.
What the cancer vaccine trial found
Merck (MRK) and partner Moderna said their Phase 3 INTerpath 001 trial hit its main goal, according to a company statement.
- The study tested a treatment called intismeran autogene, also known as V940 or mRNA 4157, alongside Merck’s blockbuster immunotherapy Keytruda in patients with resected stage IIB through IV melanoma, meaning the tumor had already been surgically removed.
- Patients who got the combination treatment saw statistically significant improvement in two measures: how long they stayed cancer-free, and how long they went without the cancer spreading to distant parts of the body.
- Both beat out results from patients who received Keytruda alone, the current standard treatment after surgery.
The trial matters for one simple reason. It’s the first time an individualized cancer vaccine has shown positive results in a late-stage trial.
The therapy is built directly from a patient’s own tumor sample. Doctors sequence the tumor’s genetic mutations, then design an mRNA shot that trains the immune system to recognize and attack those specific mutations, up to 34 of them.
Related: Moderna just got a signal investors can’t ignore
Notably, no two patients get the same treatment.
Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia, called it a landmark moment for adjuvant melanoma treatment.
“Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer,” Long stated.
Moderna (MRNA) CEO Stephane Bancel said the idea of a cancer treatment tailored to an individual patient had been aspirational for years and could soon be a reality.
Safety data looked consistent with earlier trials of the combination, with no new red flags reported.
Why Merck stock investors care right now
Keytruda is central to Merck’s business.
The drug and its newer formulation, Keytruda Qlex, generated $8.4 billion in sales in the second quarter, up 4% from a year earlier. It accounted for more than 50% of the company’s Q2 revenue of $16.6 billion.
Keytruda is not just Merck’s biggest product, but also one of the best-selling drugs in the world, treating everything from lung and bladder cancer to breast and cervical cancer.
But Keytruda’s patent protection will not last forever, and Wall Street has spent years asking what comes next.
More Healthcare/Health:
- One IRA withdrawal can triple your Medicare premium
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
- Medicare’s new $50 GLP-1 deal has a catch
Chief Executive Rob Davis addressed that directly on the earnings call, telling analysts the company expects “a shallow dip with a fast return back to growth” once Keytruda faces generic competition.
A personalized cancer vaccine that works alongside Keytruda gives Merck a fresh growth story built on its existing cancer franchise.
Chief Research Officer Dean Li called the vaccine program part of a broader push toward more personalized cancer care.
Merck and Moderna are not stopping at melanoma. The two companies are running nine total trials testing the vaccine technology across lung cancer, bladder cancer, and kidney cancer, both alongside Keytruda and on its own.
What comes next for Merck stock
The trial results still need to clear regulators before doctors can prescribe the treatment widely.
Merck said the data will go to an upcoming medical conference and to health authorities for review, but gave no specific timeline for an approval decision.
Investors will also want to watch overall survival data, a key secondary goal of the study that researchers have not yet reported.
Recurrence-free survival is an encouraging early signal, but showing patients live longer often convinces doctors and insurers to embrace a new treatment fully.
Merck raised its full-year revenue guidance to a range of $66.3 billion to $67.3 billion after the second quarter, and executives pointed to faster-than-expected clinical progress across the pipeline, including this melanoma vaccine data, as a reason for growing confidence.
For a company built in the 19th century, betting big on 21st-century mRNA science to defend its cancer franchise is a notable pivot.
If the vaccine approach pans out in later trials and eventually wins approval, it could become one of the more important growth drivers in Merck’s next decade, extending the life of Keytruda that already treats millions of patients worldwide.
Related: From Vaccines to Targeted Therapy: The Future of Cancer Care
